Grifols S.A. (GRFS) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Grifols S.A. (GRFS) over the past year, gaining 104.5% versus a loss of 21.8%. Over five years, KNSA leads with a +580.9% price change compared with -47.3% for GRFS. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.06 billion vs $5.02 billion), about 1.2 times the size.
On valuation, Grifols S.A. trades at a lower forward P/E (5.1x vs 48.0x for Kiniksa Pharmaceuticals International).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | KNSA |
|---|---|---|
| Share price | $7.38 | $77.67 |
| Market cap | $5.02B | $6.06B |
| 1-day change | -1.67% | -0.37% |
| YTD return | -19.79% | +88.99% |
| 1-year return | -21.79% | +104.51% |
| 5-year return | -47.26% | +580.87% |
| P/E ratio (TTM) | 9.58 | 78.45 |
| Forward P/E | 5.11 | 48.02 |
| EPS (TTM) | $0.77 | $0.99 |
| Dividend yield | 1.41% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | — | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $9.90 | $82.94 |
| 52-week low | $6.96 | $35.20 |
| Distance from 52-week high | -25.51% | -6.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +47.39% | +26.17% |
| Average volume | 580.72K | 578.96K |
| Shares outstanding | 258.22M | 48.29M |
| Employees | 25,258 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed GRFS by 126.3 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (78.5x vs 9.6x trailing P/E).
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
GRFS vs KNSA FAQ
Which is bigger, Grifols S.A. or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.06B compared with $5.02B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, GRFS or KNSA?
KNSA returned +104.51% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GRFS or KNSA?
GRFS has the lower trailing P/E at 9.6, versus 78.5 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Grifols S.A. or Kiniksa Pharmaceuticals International?
Grifols S.A. pays a dividend yielding 1.41%, while Kiniksa Pharmaceuticals International does not currently pay a regular dividend.
Are Grifols S.A. and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.